

Electronic supplementary material

ESM Table 2 Adverse events (occurring in >1% in any treatment group) by system organ class and preferred term: safety analysis set

Class/set	Liraglutide 1.8 + OGLA			OGLA			Glargine + OGLA		
	<i>n</i>	%	E	<i>n</i>	%	E	<i>n</i>	%	E
Safety analysis set	230			114			232		
Adverse events	151	65.7	424	64	56.1	168	127	54.7	295
Gastrointestinal disorders	87	37.8	157	18	15.8	27	18	7.8	31
Nausea	32	13.9	41	4	3.5	4	3	1.3	3
Diarrhoea	23	10.0	29	6	5.3	7	3	1.3	6
Dyspepsia	15	6.5	16	1	0.9	1	4	1.7	4
Vomiting	15	6.5	18	4	3.5	4	1	0.4	1
Abdominal pain upper	10	4.3	14	2	1.8	3	2	0.9	3
Constipation	5	2.2	5				2	0.9	3
Toothache	5	2.2	5				3	1.3	3
Abdominal discomfort	3	1.3	6	2	1.8	3	1	0.4	1
Abdominal distension	3	1.3	4	1	0.9	1	1	0.4	1
Gastritis	3	1.3	3				1	0.4	1
Infections and infestations	51	22.2	72	36	31.6	45	63	27.2	89
Nasopharyngitis	21	9.1	23	10	8.8	10	26	11.2	32
Bronchitis	7	3.0	7	1	0.9	1	3	1.3	3
Gastroenteritis	3	1.3	3	1	0.9	1	3	1.3	3
Urinary tract infection	3	1.3	4	2	1.8	2	3	1.3	3
Viral infection	3	1.3	3	1	0.9	1	2	0.9	2
Influenza	2	0.9	2	5	4.4	5	8	3.4	9
Pharyngitis	2	0.9	2	5	4.4	5	2	0.9	3
Acute tonsillitis	1	0.4	2				3	1.3	4
Lower respiratory tract infection	1	0.4	1	1	0.9	2	3	1.3	3
Pneumonia				2	1.8	2	3	1.3	3
Sinusitis				2	1.8	2	3	1.3	3
Nervous system disorders	29	12.6	43	11	9.6	18	24	10.3	32
Headache	22	9.6	33	9	7.9	14	13	5.6	18
Dizziness	3	1.3	3	2	1.8	2	1	0.4	1
Musculoskeletal and connective tissue disorders	22	9.6	35	15	13.2	20	34	14.7	43
Back pain	7	3.0	17	3	2.6	3	8	3.4	10
Arthralgia	4	1.7	4	3	2.6	3	6	2.6	8
Musculoskeletal pain	3	1.3	3	2	1.8	2	4	1.7	4
Neck pain	3	1.3	4				1	0.4	1
Muscle spasms	2	0.9	3	3	2.6	3	3	1.3	3
Myalgia				1	0.9	1	3	1.3	3
Metabolism and nutrition disorders	20	8.7	23	7	6.1	7	5	2.2	5
Anorexia	10	4.3	10	1	0.9	1			
Dyslipidaemia	3	1.3	3	3	2.6	3	1	0.4	1
General disorders and administration site condition	13	5.7	15	4	3.5	5	10	4.3	13
Pyrexia	5	2.2	5	1	0.9	1	5	2.2	7
Investigations	12	5.2	14	2	1.8	3	6	2.6	8
Blood calcitonin increased	3	1.3	3						
Cardiac disorders	10	4.3	10	4	3.5	4	9	3.9	10
Eye disorders	8	3.5	8	4	3.5	4	10	4.3	11
Diabetic retinopathy	2	0.9	2	3	2.6	3	4	1.7	4
Vascular disorders	8	3.5	8	5	4.4	5	8	3.4	8
Hypertension	7	3.0	7	3	2.6	3	5	2.2	5
Respiratory, thoracic and mediastinal disorders	7	3.0	9	6	5.3	8	10	4.3	17
Cough	4	1.7	6	1	0.9	1	7	3.0	12
Pharyngolaryngeal pain	2	0.9	2	2	1.8	3	1	0.4	1
Psychiatric disorders	4	1.7	4	7	6.1	8			
Depression	2	0.9	2	3	2.6	3			
Anxiety	1	0.4	1	3	2.6	3			
Skin and subcutaneous tissue disorders	4	1.7	6				5	2.2	6
Rash	3	1.3	5				2	0.9	2
Ear and labyrinth disorders	3	1.3	3	2	1.8	2	2	0.9	3
Vertigo	3	1.3	3				1	0.4	2
Motion sickness				2	1.8	2			
Hepatobiliary disorders	3	1.3	3	1	0.9	1			
Renal and urinary disorders	3	1.3	3	1	0.9	1	7	3.0	7
Reproductive system and breast disorders	3	1.3	3						
Injury, poisoning and procedural complications	1	0.4	1	6	5.3	7	8	3.4	8
Fall				2	1.8	2	1	0.4	1

E, number of adverse events; *n*, number of participants with adverse event; OGLA, oral glucose-lowering agent; %, proportion of participants in analysis set having adverse events